• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Xeris Pharmaceuticals Inc (NQ: XERS )

    2.900 +0.020 (+0.69%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 928,116
    Open 2.920
    Bid (Size) 2.830 (3)
    Ask (Size) 2.920 (10)
    Prev. Close 2.880
    Today's Range 2.830 - 2.930
    52wk Range 1.460 - 3.260
    Shares Outstanding 66,497,370
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Xeris to Participate in Upcoming Investor Conferences
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    More Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying
    Via Benzinga

    Performance

    YTD
    +28.04%
    +28.04%
    1 Month
    +11.11%
    +11.11%
    3 Month
    +51.04%
    +51.04%
    6 Month
    -6.75%
    -6.75%
    1 Year
    +27.75%
    +27.75%

    More News

    Read More
    Xeris Biopharma And 2 Other Penny Stocks Insiders Are Buying
    Via Benzinga
    XERS Stock Earnings: Xeris Biopharma Holdings Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Xeris Biopharma Reports Second Quarter 2024 Financial Results
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics
    Via ACCESSWIRE
    Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Xeris Biopharma Announces CEO Succession Plan
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Xeris to Participate in the Jefferies Global Healthcare Conference
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Socket Mobile And 3 Other Stocks Under $3 Insiders Are Buying
    Via Benzinga
    XERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Why Are Xeris Biopharma Shares Moving Monday?
    Via Benzinga
    Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Earnings Scheduled For March 6, 2024
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.